{ "document_metadata": { "page_number": "53", "document_number": "3-2", "date": "07/08/2022", "document_type": "Court Document", "has_handwriting": false, "has_stamps": false }, "full_text": "Case 22-1426, Document 3-2, 07/08/2022, 3344434, Page53 of 92\n\n| Date | Number | Description |\n|------------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|\n| 10/29/2021 | 392 | MOTION in Limine to Suppress Identification. Document filed by Ghislaine Maxwell. (Attachments: # 1 Exhibit A)(Pagliuca, Jeffrey) (Entered: 10/29/2021) |\n| 10/29/2021 | 393 | MOTION in Limine to Preclude Law Enforcement Witnesses from Offering Expert Opinion Testimony. Document filed by Ghislaine Maxwell. (Pagliuca, Jeffrey) |\n| | | (Entered: 10/29/2021) |\n| 10/29/2021 | 394 | MOTION in Limine to Preclude Testimony About Any Alleged \"Rape\" by Jeffrey Epstein. Document filed by Ghislaine Maxwell. (Pagliuca, Jeffrey) (Entered: |\n| | | 10/29/2021) |\n| 10/29/2021 | 395 | MOTION in Limine to Preclude Reference to the Accusers as \"Victims\" or \"Minor Victims\". Document filed by Ghislaine Maxwell. (Pagliuca, Jeffrey) (Entered: |\n| | | 10/29/2021) |\n| 10/29/2021 | 396 | MOTION in Limine to Preclude Introduction of Government's Exhibits 251, 288, 294, 313 and 606. Document filed by Ghislaine Maxwell. (Attachments: # 1 Exhibit |\n| | | A)(Pagliuca, Jeffrey) (Entered: 10/29/2021) |\n| 10/29/2021 | 397 | RESPONSE in Opposition by USA as to Ghislaine Maxwell re: 386 MOTION in Limine to Exclude Under Federal Rule of Evidence 702 and Daubert v. Merrell Dow |\n| | | Pharmaceuticals, Inc., 509 U.S. 579 (1993) and Request for Daubert Hearing., 396 MOTION in Limine to Preclude Introduction of Government's Exhibits 251, 288, |\n| | | 294, 313 and 606., 390 MOTION in Limine to Exclude Government Exhibit 52, an Unauthenticated Hearsay Document from Suspect Sources., 389 MOTION in Limine to |\n| | | Exclude Evidence of Alleged False Statement Evidence., 388 MOTION in Limine to Exclude Evidence of Alleged Flight., 387 MOTION in Limine to Exclude Evidence |\n| | | Related to Accuser-3., 384 MOTION in Limine to Preclude the Introduction of Alleged Co-Conspirator Statements as a Sanction for Failing to Comply with This |\n| | | Court's September 3, 2021 Order., 395 MOTION in Limine to Preclude Reference to the Accusers as \"Victims\" or \"Minor Victims\"., 385 MOTION in Limine to |\n| | | Exclude Any Evidence Offered by the Government Pursuant to Fed. R. Evid. 404(b) for Failure to Comply with the Rule's Notice Requirement., 394 MOTION in |\n| | | Limine to Preclude Testimony About Any Alleged \"Rape\" by Jeffrey Epstein., 391 MOTION in Limine to Exclude Items Purportedly Seized During Search of 358 El |\n| | | Brillo Way on October 20, 2005., 392 MOTION in Limine to Suppress Identification., 393 MOTION in Limine to Preclude Law Enforcement Witnesses from Offering |\n| | | Expert Opinion Testimony.. (Attachments: # 1 Exhibit Exhibit A, # 2 Exhibit Exhibit B)(Rohrbach, Andrew) (Entered: 10/29/2021) |\n| 10/29/2021 | 398 | REPLY TO RESPONSE to Motion by Ghislaine Maxwell re 386 MOTION in Limine to Exclude Under Federal Rule of Evidence 702 and Daubert v. Merrell Dow |\n| | | Pharmaceuticals, Inc., 509 U.S. 579 (1993) and Request for Daubert Hearing., 396 MOTION in Limine to Preclude Introduction of Government's Exhibits 251, 288, |\n| | | 294, 313 and 606., 390 MOTION in Limine to Exclude Government Exhibit 52, an Unauthenticated Hearsay Document from Suspect Sources., 389 MOTION in Limine to |\n| | | Exclude Evidence of Alleged False Statement Evidence., 388 MOTION in Limine to Exclude Evidence of Alleged Flight., 387 MOTION in Limine to Exclude Evidence |\n| | | Related to Accuser-3., 384 MOTION in Limine to Preclude the Introduction of Alleged Co-Conspirator Statements as a Sanction for Failing to Comply with This |\n| | | Court's September 3, 2021 Order., 395 MOTION in Limine to Preclude Reference to the Accusers as \"Victims\" or \"Minor Victims\"., 385 MOTION in Limine to |\n| | | Exclude Any Evidence Offered by the Government Pursuant to Fed. R. Evid. 404(b) for Failure to Comply with the Rule's Notice Requirement., 394 MOTION in |\n| | | Limine to Preclude Testimony About Any Alleged \"Rape\" by Jeffrey Epstein., 391 MOTION in Limine to Exclude Items Purportedly Seized During Search of 358 El |\n| | | Brillo Way on October 20, 2005., 392 MOTION in Limine to Suppress Identification., 393 MOTION in Limine to Preclude Law Enforcement Witnesses from Offering |\n| | | Expert Opinion Testimony.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E)(Pagliuca, Jeffrey) (Entered: 10/29/2021) |\n| 10/29/2021 | 399 | JOINT LETTER by USA as to Ghislaine Maxwell addressed to Judge Alison J. Nathan from AUSAs Alison Moe, Lara Pomerantz, and Andrew Rohrbach dated Oct. 28, |\n| | | 2021 re: Justifications for redactions Document filed by USA. (Rohrbach, Andrew) (Entered: 10/29/2021) |\n\nDOJ-OGR-00020539", "text_blocks": [ { "type": "printed", "content": "Case 22-1426, Document 3-2, 07/08/2022, 3344434, Page53 of 92", "position": "header" }, { "type": "printed", "content": "The rest of the content is a table with various court documents and their descriptions.", "position": "body" }, { "type": "printed", "content": "DOJ-OGR-00020539", "position": "footer" } ], "entities": { "people": [ "Ghislaine Maxwell", "Jeffrey Epstein", "Jeffrey Pagliuca", "Alison J. Nathan", "Alison Moe", "Lara Pomerantz", "Andrew Rohrbach" ], "organizations": [ "USA", "AUSAs" ], "locations": [], "dates": [ "10/29/2021", "07/08/2022", "10/29/2021", "10/20/2005", "September 3, 2021", "Oct. 28, 2021" ], "reference_numbers": [ "22-1426", "3-2", "3344434", "392", "393", "394", "395", "396", "397", "398", "399", "386", "390", "389", "388", "387", "384", "385", "391", "251", "288", "294", "313", "606", "52" ] }, "additional_notes": "The document appears to be a court docket sheet with various motions and responses filed in a case involving Ghislaine Maxwell. The document is well-formatted and legible." }